Gabelli Funds LLC Lowers Holdings in Catalent, Inc. (NYSE:CTLT)

Gabelli Funds LLC lowered its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 2.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 445,671 shares of the company’s stock after selling 10,476 shares during the quarter. Gabelli Funds LLC owned approximately 0.25% of Catalent worth $25,060,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CTLT. Vanguard Group Inc. lifted its stake in Catalent by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock worth $1,151,872,000 after purchasing an additional 218,682 shares in the last quarter. Capital World Investors lifted its position in shares of Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after buying an additional 1,098,474 shares in the last quarter. Cadian Capital Management LP boosted its stake in Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares during the last quarter. Capital International Investors raised its holdings in shares of Catalent by 1.2% during the 4th quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock worth $134,541,000 after acquiring an additional 34,856 shares in the last quarter. Finally, Alpine Associates Management Inc. boosted its position in shares of Catalent by 3.8% during the 2nd quarter. Alpine Associates Management Inc. now owns 2,061,251 shares of the company’s stock valued at $115,904,000 after acquiring an additional 75,700 shares during the last quarter.

Catalent Stock Performance

Catalent stock opened at $60.00 on Monday. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The company’s 50-day moving average is $59.48 and its 200 day moving average is $57.22. The firm has a market capitalization of $10.86 billion, a P/E ratio of -9.84, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CTLT shares. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com began coverage on shares of Catalent in a research report on Wednesday, September 18th. They set a “sell” rating on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Finally, Barclays upped their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $58.08.

Insider Transactions at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is currently owned by company insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.